• Accelrys Inc., of San Diego, reported that its Accord Chemistry Control cheminformatics component will be used to enable chemical depiction in GenSys Software's Electronic Laboratory Notebook. GenSys will embed the Accelrys Accord Chemistry Control into its ELN software, enhancing the electronic notebook with high-quality depiction of chemical structures.

• Cellegy Pharmaceuticals Inc., of South San Francisco, completed its reincorporation from the state of California to the state of Delaware. Cellegy's shareholders approved the reincorporation proposal at its annual meeting of shareholders on June 15. The reincorporation was accomplished with the merger of Cellegy into its wholly owned subsidiary, which is incorporated in Delaware. Cellegy focuses on gastrointestinal disorders, sexual dysfunction, women's health care conditions and certain cancers.

• Connetics Corp., of Palo Alto, Calif., said the FDA said it made an administrative error when assigning the original user-fee goal date for Extina (2 percent ketoconazole). During the course of the ongoing review of the Extina new drug application, the FDA acknowledged that the original user-fee goal date of Sept. 24 was assigned in error and that the correct date is Nov. 26. Extina is an investigational new drug formulation for seborrheic dermatitis. Connetics said commercial planning for Extina, as well as previously announced sales force expansion plans and financial guidance for 2004, are unchanged.

• Nautilus Biotech SA, of Paris, and Creabilis Therapeutics SRL, of Ivrea, Italy, signed a collaboration agreement for the identification and development of an improved variant of CT500, a non-antibody protein selected by Creabilis, with antagonist activity against HMGB1. The anti-HMGB1 variant protein is expected to have potential applications in autoimmune diseases, infectious diseases, sepsis, tumors, cardiovascular and also neurologic and amyloid pathologies. Financial terms were not disclosed.

• Senetek plc, of Napa, Calif., said its appeal hearing with the Nasdaq Listing Qualifications Panel related to its continued listing on the Nasdaq SmallCap Market has been rescheduled from Sept. 23 to Sept. 30. If Senetek's stock is delisted, its American depository shares will trade on the Over-the-Counter Bulletin Board, and the company will work to improve its financial position in order to relist at a later date on Nasdaq or another national stock exchange. The company, which is developing anti-aging products, is facing delisting due to non-compliance with a minimum continued listing standard.

• Senomyx Inc., of La Jolla, Calif., said its scientists discovered the binding specificity of certain bitter-tasting compounds for the human bitter-taste receptors, T2R44 and T2R61. It also said the results have been published in the September issue of Chemical Senses.

• Serono SA, of Geneva, said that in connection with the grant of a license under a non-core technology, it is to receive a license fee, payable in annual installments over the next three years. The licensee fee is received instead of future ongoing royalties and will be recognized immediately as license income in Serono's third-quarter results. The identity of the licensee was not disclosed.

• V.I. Technologies Inc., of Watertown, Mass., reported that, as required, the Nasdaq Stock Market notified the company that the bid price of its stock closed below the minimum price of $1 per share over the previous 30 consecutive trading days, and that it will be provided 180 calendar days, or until Feb. 28, to regain compliance with the minimum bid price requirement.

• Xenova Group plc, of Slough, UK, completed the sale of its manufacturing facility in Edmonton, Alberta, to Edmonton-based QSV Biologics Ltd. for C$7 million (US$5.4 million). The sale concludes the planned disposals and cost-reduction program announced at the time of the KS Biomedix plc acquisition last year. Proceeds from the sale will be used to fund expenses relating to Xenova's programs. Xenova also agreed to a manufacturing and supply contract with QSV for TransMID, which is in Phase III trials for high-grade glioma. All 30 of Xenova's employees at the facility, including those involved n the production of TransMID, transferred to QSV.

No Comments